ARUP LABORATORIES
800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Chief Medical Officer



Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

## Patient: Patient, Example

| | |
|---|---|
| **DOB** | 2/8/1989 |
| **Gender:** | Male |
| **Patient Identifiers:** | 01234567890ABCD, 012345 |
| **Visit Number (FIN):** | 01234567890ABCD |
| **Collection Date:** | 00/00/0000 00:00 |

## BCL6 (3q27) Gene Rearrangement by FISH

ARUP test code 3001311

| | |
|---|---|
| BCL6 FISH Result | Negative<br><br>Controls were run and performed as expected.<br>This result has been reviewed and approved by [redacted] |
| Total Cell Count | 365 |
| Scoring Method | Computer Assisted |
| BCL6 FISH Reference Number | CLS25-509071 A9 |
| BCL6 FISH Source | Colon |

H=High, L=Low, *=Abnormal, C=Critical

INTERPRETIVE INFORMATION: BCL6 (3q27) Gene Rearrangement, FISH

BCL6 fluorescence in situ hybridization (FISH) analysis is designed to detect 3q27 (BCL6) translocations regardless of rearrangement partners. Differentially labelled probes targeting the upstream (5') and downstream (3') flanking regions of the BCL6 gene were used (Agilent Technologies).

When 12 percent or more of the cells evaluated show an abnormal signal pattern, it is considered a positive result. Some signal patterns other than the classic abnormal pattern may also be present and may be considered abnormal.

BCL6 rearrangement is commonly found in diffuse large B-cell lymphomas (DLBCL) and follicular lymphomas. Results should be correlated with clinical, morphologic and immunophenotypic data. Based on the assay performance during test validation, the test is expected to detect 100 percent of BCL6 rearrangements in patients with BCL6-rearranged lymphomas, except for rare instances of cryptic rearrangements. Assay range and limit of detection were generated using normal and known positive cases respectively.

Fluorescence in situ hybridization (FISH) analysis was performed on a section from a paraffin-embedded tissue block. The area(s) for analysis were selected by histopathologic review of a matching hematoxylin- and eosin-stained section.

Controls performed appropriately.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

VERIFIED/REPORTED DATES

| Procedure | Accession | Collected | Received | Verified/Reported |
|---|---|---|---|---|
| BCL6 FISH Result | 25-280-166984 | 00/00/0000 00:00 | 00/00/0000 00:00 | 00/00/0000 00:00 |
| Total Cell Count | 25-280-166984 | 00/00/0000 00:00 | 00/00/0000 00:00 | 00/00/0000 00:00 |
| Scoring Method | 25-280-166984 | 00/00/0000 00:00 | 00/00/0000 00:00 | 00/00/0000 00:00 |
| BCL6 FISH Reference Number | 25-280-166984 | 00/00/0000 00:00 | 00/00/0000 00:00 | 00/00/0000 00:00 |
| BCL6 FISH Source | 25-280-166984 | 00/00/0000 00:00 | 00/00/0000 00:00 | 00/00/0000 00:00 |

END OF CHART

**H=High, L=Low, *=Abnormal, C=Critical**